RESUMO
BACKGROUND: Peripheral neuropathy is a common comorbidity in COPD. We aimed to investigate associations between alterations commonly found in COPD and peripheral neuropathy, with particular emphasize on the distinction between direct and indirect effects. METHODS: We used visit 4 data of the COPD cohort COSYCONET, which included indicators of polyneuropathy (repeated tuning fork and monofilament testing), excluding patients with diabetes a/o increased HbA1c. These indicators were analysed for the association with COPD characteristics, including lung function, blood gases, 6-min walk distance (6-MWD), timed-up-and-go-test (TUG), exacerbation risk according to GOLD, C-reactive protein (CRP), and ankle-brachial index (ABI). Based on the results of conventional regression analyses adjusted for age, BMI, packyears and gender, we utilized structural equation modelling (SEM) to quantify the network of direct and indirect relationships between parameters. RESULTS: 606 patients were eligible for analysis. The indices of polyneuropathy were highly correlated with each other and related to base excess (BE), ABI and TUG. ABI was linked to neuropathy and 6-MWD, exacerbations depended on FEV1, 6-MWD and CRP. The associations could be summarized into a SEM comprising polyneuropathy as a latent variable (PNP) with three measured indicator variables. Importantly, PNP was directly dependent on ABI and particularly on BE. When also including patients with diabetes and/or elevated values of HbA1c (n = 742) the SEM remained virtually the same. CONCLUSION: We identified BE and ABI as major determinants of peripheral neuropathy in patients with COPD. All other associations, particularly those with lung function and physical capacity, were indirect. These findings underline the importance of alterations of the micromilieu in COPD, in particular the degree of metabolic compensation and vascular status.
Assuntos
Polineuropatias/epidemiologia , Polineuropatias/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Idoso , Índice Tornozelo-Braço/tendências , Estudos de Coortes , Comorbidade , Estudos Transversais , Feminino , Alemanha/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Polineuropatias/diagnóstico , Doença Pulmonar Obstrutiva Crônica/diagnósticoRESUMO
BACKGROUND: Injection of botulinum neurotoxin A (BoNT-A) according to the PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) paradigm has been approved for the treatment of refractory chronic migraine in Germany in 2011. OBJECTIVE: The practical application raises some questions, such as the choice of dose and injection intervals during the course of the treatment, and the appropriate time point for discontinuation of BoNT-A treatment. MATERIAL AND METHODS: Taking into account the existing literature, the German Migraine and Headache Society (Deutsche Migräne- und Kopfschmerzgesellschaft, DMKG) gives recommendations for the treatment of chronic migraine with BoNT-A. RESULTS: Treatment is usually started with a dose of 155 U BoNT-A. During the first year of treatment, 3month injection intervals are recommended. Goal of the treatment is an improvement of migraine by ≥30%. If needed, dose escalation up to 195 U can be used to reach this goal. If improvement by ≥30% is not reached after the third injection cycle, the treatment is usually considered to be insufficiently efficient and discontinuation is recommended. If a stable success is reached during the first year of treatment, prolongation of injection intervals to 4 months can be considered. If success continues to be stable for at least two 4month intervals, discontinuation of BoNT-A treatment can be tried. CONCLUSION: The literature on these points is insufficient for recommendations at the guideline level. The present recommendations are based on an expert consensus of the DMKG for the structured approach to the treatment of chronic migraine with BoNT-A.
Assuntos
Toxinas Botulínicas Tipo A , Transtornos de Enxaqueca , Toxinas Botulínicas Tipo A/uso terapêutico , Alemanha , Humanos , Transtornos de Enxaqueca/tratamento farmacológico , Fármacos Neuromusculares/uso terapêuticoRESUMO
Besides pharmacological and interventional possibilities nonpharmacological options, deriving from behavioural approaches may be helpful in the treatment of migraine. Already consulting a patient reduces frequency of attacks. Relaxation (especially progressive muscle relaxation), endurance sports, and biofeedback as well as cognitive behavioural therapy are effective in treatment of migraine. The combination of these treatment options also with pharmacological treatment increase the positive effects.
RESUMO
This consensus paper introduces a classification of headache care facilities on behalf of the German Migraine and Headache Society. This classification is based on the recommendations of the International Association for the Study of Pain (IASP) and the European Headache Federation (EHF) and was adapted to reflect the specific situation of headache care in Germany. It defines three levels of headache care: headache practitioner (level 1), headache outpatient clinic (level 2) and headache centers (level 3). The objective of the publication is to define and establish reliable criteria in the field of headache care in Germany.
Assuntos
Atenção à Saúde/classificação , Atenção à Saúde/organização & administração , Transtornos da Cefaleia/terapia , Transtornos de Enxaqueca/terapia , Clínicas de Dor/classificação , Clínicas de Dor/organização & administração , Sociedades Médicas , Instituições de Assistência Ambulatorial/classificação , Instituições de Assistência Ambulatorial/organização & administração , Alemanha , Humanos , Comunicação Interdisciplinar , Equipe de Assistência ao Paciente/organização & administraçãoRESUMO
Symptoms and signs of primary headache disorders can change during one's lifetime. Moreover, the impact and the frequency of attacks can fluctuate in an individual patient over time. Before puberty, boys and girls are equally affected; after puberty most headache disorders predominate in women. The treatment of primary headache disorders always has to take into consideration the severity and the frequency of headache attacks as well as the relevant comorbidities. Prophylactic headache treatment can modulate the course of primary headache disorders. Specific prophylactic treatment is the most important instrument for avoiding headache chronification caused by medication overuse. While primary headache disorders tend to improve in elderly patients, secondary headache disorders peak in elderly people. They are often a symptom of oncologic diseases, vascular disorders, or are linked to side effects of drugs that are prescribed more frequently in the elderly. The treatment and the prognosis of secondary headache disorders always depend on the underlying disease.
Assuntos
Transtornos da Cefaleia/epidemiologia , Transtornos da Cefaleia/terapia , Adolescente , Adulto , Distribuição por Idade , Idoso , Doença Crônica , Feminino , Transtornos da Cefaleia/classificação , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Remissão Espontânea , Fatores de Risco , Distribuição por Sexo , Adulto JovemRESUMO
Chronic migraine (CM) was first defined in the second edition of the International Headache Society (IHS) classification in 2004. The definition currently used (IHS 2006) requires the patient to have headache on more than 15 days/month for longer than 3 months and a migraine headache on at least 8 of these monthly headache days and that there is no medication overuse. In daily practice the majority of the patients with CM also report medication overuse but it is difficult to determine whether the use is the cause or the consequence of CM. Most the patients also have other comorbidities, such as depression, anxiety and chronic pain at other locations. Therapy has to take this complexity into consideration and is generally multimodal with behavioral therapy, aerobic training and pharmacotherapy. The use of analgesics should be limited to fewer than 15 days per month and use of triptans to fewer than 10 days per month. Drug treatment should be started with topiramate, the drug with the best scientific evidence. If there is no benefit, onabotulinum toxin A (155-195 Units) should be used. There is also some limited evidence that valproic acid and amitriptyline might be beneficial. Neuromodulation by stimulation of the greater occipital nerve or vagal nerve is being tested in studies and is so far an experimental procedure only.
Assuntos
Transtornos de Enxaqueca/diagnóstico , Transtornos de Enxaqueca/terapia , Neurologia/normas , Áustria , Doença Crônica , Alemanha , Humanos , SuíçaAssuntos
Transtornos de Enxaqueca/terapia , Complicações na Gravidez/terapia , Adulto , Idoso , Analgésicos/efeitos adversos , Analgésicos/uso terapêutico , Terapia Combinada , Comorbidade , Exercício Físico , Feminino , Idade Gestacional , Humanos , Masculino , Transtornos de Enxaqueca/epidemiologia , Transtornos de Enxaqueca/etiologia , Transtornos de Enxaqueca/prevenção & controle , Neurorretroalimentação , Gravidez , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/epidemiologia , Complicações na Gravidez/prevenção & controle , Terapia de Relaxamento , Fatores de RiscoAssuntos
Cefaleia/etiologia , Fatores Etários , Idoso , Estudos Transversais , Diagnóstico Diferencial , Alemanha , Cefaleia/epidemiologia , Cefaleia/terapia , Humanos , Pessoa de Meia-Idade , Transtornos de Enxaqueca/epidemiologia , Transtornos de Enxaqueca/etiologia , Transtornos de Enxaqueca/terapia , Cefaleia do Tipo Tensional/epidemiologia , Cefaleia do Tipo Tensional/etiologia , Cefaleia do Tipo Tensional/terapiaAssuntos
Transtornos da Cefaleia/etiologia , Hipertensão Intracraniana/etiologia , Obesidade/complicações , Sobrepeso/complicações , Apneia Obstrutiva do Sono/etiologia , Diagnóstico Diferencial , Jejum/efeitos adversos , Transtornos da Cefaleia/diagnóstico , Humanos , Hipertensão Intracraniana/diagnóstico , Obesidade/dietoterapia , Sobrepeso/dietoterapia , Apneia Obstrutiva do Sono/diagnósticoRESUMO
The CSF-pressure-lowering effects of indomethacin in seven patients with idiopathic intracranial hypertension and one patient with symptomatic intracranial hypertension due to a non-space-occupying meningioma are reported. CSF opening pressure between 350 and 500 mm H2O (mean 400 mm H2O) was promptly reduced by 80 to 200 mm H2O (mean reduction, 139 mm H2O) for at least 10 minutes in all patients after IV administration of 50 mg indomethacin. Four patients had mild and transient side effects (dizziness). Indomethacin might be an alternative drug for treatment of intracranial hypertension.
Assuntos
Pressão do Líquido Cefalorraquidiano/efeitos dos fármacos , Indometacina/uso terapêutico , Hipertensão Intracraniana/tratamento farmacológico , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Cervical MRI of eight patients with severe orthostatic headache showed a convex-shaped, prominent, dilated anterior, internal vertebral venous plexus with a flow-void signal in all patients and in seven also extra arachnoid fluid collection. Follow-up MRI showed resolution of the abnormalities in all patients. The authors hypothesize that these findings reflect disturbed compensatory vascular mechanisms by which autoregulation of the CSF pressure tries to compensate for the reduced CSF volume.
Assuntos
Espaço Epidural/irrigação sanguínea , Espaço Epidural/patologia , Cefaleia/patologia , Adulto , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-IdadeRESUMO
Oral administration of zolmitriptan, a novel 5-hydroxytriptamine receptor agonist, to eight healthy volunteers significantly reduced motor cortical excitability as tested by paired transcranial magnetic stimulation (TMS) at short interstimulus intervals. Zolmitriptan did not change motor thresholds to TMS or electromyographic silent period durations. We conclude that zolmitriptan acts centrally by reducing the inhibition within the motor cortex. The results suggest that the action of zolmitriptan on motor cortical excitability does not result from changes at the level of the cell membrane but from the influence on GABAergic inhibitory interneurons.
Assuntos
Córtex Motor/efeitos dos fármacos , Oxazóis/farmacologia , Oxazolidinonas , Agonistas do Receptor de Serotonina/farmacologia , Adulto , Encéfalo/efeitos dos fármacos , Encéfalo/fisiologia , Eletromiografia , Feminino , Humanos , Masculino , Córtex Motor/fisiologia , Receptores de Serotonina/efeitos dos fármacos , TriptaminasRESUMO
We report a 19-year-old patient who presented with an acute encephalopathy manifested by catatonia. We isolated Borrelia burgdorferi from the CSF and demonstrated intrathecal production of IgG antibodies against B burgdorferi. The patient completely recovered after intravenous ceftriaxone therapy.
Assuntos
Catatonia/etiologia , Encefalite/microbiologia , Doença de Lyme/complicações , Doença Aguda , Adulto , Catatonia/líquido cefalorraquidiano , Encefalite/líquido cefalorraquidiano , Encefalite/complicações , Humanos , Masculino , SíndromeRESUMO
To investigate neglect, extinction, and body-perception in patients suffering from complex regional pain syndrome (CRPS). So-called 'neglect-like' symptoms have been reported in CRPS, however no studies have yet analyzed this phenomenon which might substantiate the theory of the central nervous system involvement in the pathophysiology of CRPS. A total of 114 patients with CRPS of the upper limb underwent bedside neurological examination. 'Neglect-like' symptoms were determined by asking all patients what kind of feeling they had toward the affected hand (feeling of foreignness). Hemispatial neglect was tested with the line bisection task in 29 patients and sensory extinction to simultaneous stimulation in 40 patients. The ability to identify fingers after tactile stimulation was tested in 73 patients. Independently of the affected side and disease duration, 54.4% of the patients reported that their hand felt 'foreign' or 'strange'. The ability to identify fingers was impaired in 48% on the affected hand and in 6.5% on the unaffected hand ( X(2) = 33.52, df = 1, p < 0.0001). These findings were related to pain intensity, illness duration and the extent of sensory deficits. No typical abnormalities indicating neglect were found in the line bisection test. Sensory extinction was normal in all patients. A large proportion of CRPS patients have disturbances of the self-perception of the hand, indicating an alteration of higher central nervous system processing. There are no indicators that classic neglect or extinction contribute to these findings. Physical therapy of such patients should take this observation into consideration.